Oncopharmpod
Zongertinib
- Autor: Vários
- Narrador: Vários
- Editor: Podcast
- Duración: 0:12:07
- Mas informaciones
Informações:
Sinopsis
A new ERBB2 (HER2) targeting TKI is approved for NSCLC. We review the characteristics of the drug and summarize the current landscape in treating HER-mutated advanced NSCLC.
